[go: up one dir, main page]

EA200801174A1 - Антитела-миметики glp-2, полипептиды, композиции, способы и применения - Google Patents

Антитела-миметики glp-2, полипептиды, композиции, способы и применения

Info

Publication number
EA200801174A1
EA200801174A1 EA200801174A EA200801174A EA200801174A1 EA 200801174 A1 EA200801174 A1 EA 200801174A1 EA 200801174 A EA200801174 A EA 200801174A EA 200801174 A EA200801174 A EA 200801174A EA 200801174 A1 EA200801174 A1 EA 200801174A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
glp
methods
compositions
applications
Prior art date
Application number
EA200801174A
Other languages
English (en)
Inventor
Одри Е. Бейкер
Беверли А. Мур
Томас К. Несспор
Кэрин О`НИЛ
Джеффри М. Палмер
Кристен Пича
Сара Сагью
Original Assignee
Сентокор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентокор, Инк. filed Critical Сентокор, Инк.
Publication of EA200801174A1 publication Critical patent/EA200801174A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Описаны антитела-миметики, полипептиды и нуклеиновые кислоты GLP-2 млекопитающих. Описаны также способы применения этих антител-миметиков и полипептидов для лечения связанных с GLP-2 заболеваний.
EA200801174A 2005-10-24 2006-10-24 Антитела-миметики glp-2, полипептиды, композиции, способы и применения EA200801174A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72970405P 2005-10-24 2005-10-24
US82416006P 2006-08-31 2006-08-31
US86248706P 2006-10-23 2006-10-23
PCT/US2006/060197 WO2007067828A2 (en) 2005-10-24 2006-10-24 Glp-2 mimetibodies, polypeptides, compositions, methods and uses

Publications (1)

Publication Number Publication Date
EA200801174A1 true EA200801174A1 (ru) 2009-02-27

Family

ID=38123579

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801174A EA200801174A1 (ru) 2005-10-24 2006-10-24 Антитела-миметики glp-2, полипептиды, композиции, способы и применения

Country Status (11)

Country Link
US (1) US20070212355A1 (ru)
EP (1) EP1948785B1 (ru)
JP (1) JP2009514508A (ru)
KR (1) KR20080071134A (ru)
AU (1) AU2006321743A1 (ru)
BR (1) BRPI0617515A2 (ru)
CA (1) CA2627444A1 (ru)
EA (1) EA200801174A1 (ru)
IL (1) IL190781A0 (ru)
NO (1) NO20082240L (ru)
WO (1) WO2007067828A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795594C2 (ru) * 2017-11-06 2023-05-05 Такеда Фармасьютикалс Ю.С.А., Инк. Пептитело glp-2 для введения до, в течение или после хирургического вмешательства

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2030419B1 (en) 2006-06-07 2017-07-19 QUALCOMM Incorporated Efficient over the air address methods and apparatus
JP5290177B2 (ja) 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
US20090022720A1 (en) * 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
JP2019528082A (ja) * 2016-06-08 2019-10-10 シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
EP3526242A1 (en) * 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
EP3672621A4 (en) * 2017-08-22 2021-11-24 Shire-NPS Pharmaceuticals, Inc. GLP-2 FUSION POLYPEPTIDES AND THEIR USES TO TREAT AND PREVENT GASTROINTESTINAL DISORDERS
CA3079523A1 (en) 2017-11-06 2019-05-09 Shire-Nps Pharmaceuticals, Inc. Glp-2 analogs and peptibodies for administration before, during or after surgery
KR20210082189A (ko) * 2018-10-24 2021-07-02 샤이어-엔피에스 파마슈티칼즈, 인크. Glp-2 융합 폴리펩티드 및 위장 병태를 치료 및 예방하기 위한 용도
PH12022550852A1 (en) 2019-10-07 2023-05-03 Kallyope Inc Gpr119 agonists
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
IL315253A (en) * 2022-03-03 2024-10-01 Univ Pennsylvania Viral vectors encoding glp-2 receptor agonist fusions and uses thereof in treating short bowel syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
EP1360202B1 (en) * 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
BR0207854A (pt) * 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
AU2003256336A1 (en) * 2002-06-28 2004-01-19 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
ATE525395T1 (de) * 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
AU2004308952A1 (en) * 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
WO2005097175A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
JP2008537874A (ja) * 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795594C2 (ru) * 2017-11-06 2023-05-05 Такеда Фармасьютикалс Ю.С.А., Инк. Пептитело glp-2 для введения до, в течение или после хирургического вмешательства

Also Published As

Publication number Publication date
WO2007067828A2 (en) 2007-06-14
NO20082240L (no) 2008-07-22
WO2007067828A3 (en) 2008-04-10
WO2007067828A9 (en) 2008-05-29
CA2627444A1 (en) 2007-06-14
KR20080071134A (ko) 2008-08-01
BRPI0617515A2 (pt) 2011-07-26
US20070212355A1 (en) 2007-09-13
AU2006321743A1 (en) 2007-06-14
EP1948785A2 (en) 2008-07-30
EP1948785B1 (en) 2014-01-15
JP2009514508A (ja) 2009-04-09
EP1948785A4 (en) 2009-02-04
IL190781A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
EA201100694A1 (ru) Антитело к cd38 человека и его применение
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
MY174493A (en) Binding agents
EA200800812A1 (ru) Композиции антитела против cd3
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
PE20140232A1 (es) Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
DK2142570T3 (da) Anti-EpCam-antistof og anvendelser deraf
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
EA200702193A1 (ru) Гликозилирование белков
ATE470478T1 (de) An ovarialkrebs beteiligtes protein